A further trial (n = 52 NAFLD patients) [84] receiving the same supplementation for 6 months denoted a reduction in the ALT, AST, GGT, inflammatory markers and liver stiffness assessed by transient elastography vs. placebo. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.